SCHEMBL717229

SCHEMBL717229

Cc1cc(F)ccc1-n1cc(C=O)c(C)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 1/20 0.40
HCAR1 Q9BXC0 1/20 0.39
RXRA P19793 5/20 0.39
GRIN1 Q05586 5/20 0.39
GRIN2B Q13224 5/20 0.39
POLB P06746 1/20 0.39
HDAC9 Q9UKV0 1/20 0.37
HTR7 P34969 1/20 0.36
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124501 0.77 POLB (0.48) ALDH1A1KDM4ERXRAGRIN1GRIN2B
SCHEMBL20550969 0.75 ALKBH1 (0.41) KDM4ERXRAGRIN1GRIN2BHDAC9
SCHEMBL716443 0.75 POLB (0.42) ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2
SCHEMBL20345173 0.74 SMN1; SMN2 (0.34) ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2
SCHEMBL717884 0.72 NPC1 (0.42) KDM4ERXRAGRIN1GRIN2BHDAC9
SCHEMBL1805377 0.71 ERN1 (0.40) ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2
SCHEMBL1808978 0.71 ALDH1A1 (0.37) ALDH1A1KDM4EPOLBHTR7KMT2A
SCHEMBL716273 0.71 ALDH1A1 (0.52) ALDH1A1KMT2ALMNATDP1
SCHEMBL16202086 0.70 MEN1 (0.45) ALDH1A1KDM4EKMT2AHTTTDP1
SCHEMBL1812768 0.70 ALDH1A1 (0.42) ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885HCAR1 1795/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885HCAR1 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.